Australia · Delayed Price · Currency is AUD Chimeric Therapeutics Company Description
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.
The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors.
It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors.
The company was incorporated in 2020 and is based in Carlton, Australia.
| Country | Australia |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Rebecca McQualter |
Contact Details
Address: 62 Lygon Street Carlton, VIC 3053 Australia | |
| Phone | 61 3 9824 5254 |
| Website | chimerictherapeutics.com |
Stock Details
| Ticker Symbol | CHM |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000121576 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rebecca McQualter | Chief Executive Officer |
| Philip Allen Hains BBus(Acc), C.A., M.B.A. | Chief Financial Officer, Joint Company Secretary and Director |
| Dr. Stephanie H. Astrow MBA, Ph.D. | Chief Scientific Officer |
| Nathan Jong C.A. | Joint Company Secretary |